

# Armida Mucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5361131/publications.pdf>

Version: 2024-02-01

171  
papers

6,291  
citations

61984

43  
h-index

79698

73  
g-index

195  
all docs

195  
docs citations

195  
times ranked

6268  
citing authors

#	ARTICLE	IF	CITATIONS
1	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	10.4	346
2	EEG microstate duration and syntax in acute, medication-naïve, first-episode schizophrenia: a multi-center study. <i>Psychiatry Research - Neuroimaging</i> , 2005, 138, 141-156.	1.8	316
3	Negative symptoms of schizophrenia: new developments and unanswered research questions. <i>Lancet Psychiatry</i> , 2018, 5, 664-677.	7.4	316
4	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. <i>Human Brain Mapping</i> , 2006, 27, 162-172.	3.6	253
5	Oxytocin receptor polymorphisms and adult attachment style in patients with depression. <i>Psychoneuroendocrinology</i> , 2009, 34, 1506-1514.	2.7	221
6	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 396.	11.0	214
7	The cortical generators of P3a and P3b: A LORETA study. <i>Brain Research Bulletin</i> , 2007, 73, 220-230.	3.0	210
8	Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. <i>Schizophrenia Research</i> , 2013, 147, 157-162.	2.0	148
9	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	7.4	141
10	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. <i>European Neuropsychopharmacology</i> , 2013, 23, 196-204.	0.7	137
11	Historical, Psychopathological, Neurological, and Neuropsychological Aspects of Deficit Schizophrenia: A Multicenter Study. <i>American Journal of Psychiatry</i> , 2002, 159, 983-990.	7.2	127
12	The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia. <i>European Psychiatry</i> , 2015, 30, 641-647.	0.2	114
13	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. <i>Schizophrenia Research</i> , 2017, 186, 19-28.	2.0	110
14	Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. <i>Psychological Medicine</i> , 2015, 45, 1765-1778.	4.5	108
15	Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. <i>Schizophrenia Research</i> , 2009, 115, 104-114.	2.0	102
16	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 305-314.	4.3	99
17	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	10.4	96
18	EPA guidance on assessment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e23.	0.2	94

#	ARTICLE	IF	CITATIONS
19	Inhibition of auditory cortical responses to ipsilateral stimuli during dichotic listening: evidence from magnetoencephalography. <i>European Journal of Neuroscience</i> , 2004, 19, 2329-2336.	2.6	90
20	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. <i>JAMA Psychiatry</i> , 2021, 78, 550.	11.0	89
21	Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 1033-1041.	4.3	88
22	Patterns of Structural MRI Abnormalities in Deficit and Nondeficit Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 393-401.	4.3	85
23	Evidence-Based Medicine and Electrophysiology in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2009, 40, 62-77.	1.7	85
24	Primary, Enduring Negative Symptoms: An Update on Research. <i>Schizophrenia Bulletin</i> , 2017, 43, 730-736.	4.3	85
25	Neurobiological background of negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 543-558.	3.2	81
26	Neuropsychological Slowness in Obsessiveâ€“Compulsive Patients. <i>British Journal of Psychiatry</i> , 1995, 167, 394-398.	2.8	78
27	Brain Hemispheric Organization, Anxiety, and Psychoses. <i>CNS Spectrums</i> , 2000, 5, 58-69.	1.2	76
28	EPA guidance on treatment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e21.	0.2	70
29	Alexithymia and Cognitive Dysfunctions in Patients with Panic Disorder. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 182-188.	8.8	66
30	Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. <i>Schizophrenia Research</i> , 2016, 175, 154-160.	2.0	66
31	Social cognition in people with schizophrenia: a cluster-analytic approach. <i>Psychological Medicine</i> , 2016, 46, 2717-2729.	4.5	65
32	The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. <i>Schizophrenia Research</i> , 2014, 159, 144-150.	2.0	64
33	Executive hypercontrol in obsessiveâ€“compulsive disorder: electrophysiological and neuropsychological indices. <i>Clinical Neurophysiology</i> , 2004, 115, 1340-1348.	1.5	60
34	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.7	60
35	Pharmaco-EEG in Psychiatry. <i>Clinical EEG and Neuroscience</i> , 2006, 37, 81-98.	1.7	59
36	Induced Gamma Activity and Event-Related Coherence in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2007, 38, 96-104.	1.7	57

#	ARTICLE	IF	CITATIONS
37	Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2007, 92, 252-261.	2.0	57
38	CEEG mapping in drug-free schizophrenics. <i>Schizophrenia Research</i> , 1991, 6, 15-23.	2.0	56
39	Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. <i>Psychiatric Genetics</i> , 2009, 19, 110-111.	1.1	56
40	Catechol-O-Methyltransferase Val <sup>158</sup> Met Polymorphism in Schizophrenia: Associations with Cognitive and Motor Impairment. <i>Neuropsychobiology</i> , 2005, 52, 83-89.	1.9	51
41	QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. <i>Biological Psychiatry</i> , 1994, 35, 367-374.	1.3	50
42	Neurocognitive functioning in subjects with eating disorders: the influence of neuroactive steroids. <i>Biological Psychiatry</i> , 2003, 53, 921-927.	1.3	50
43	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. <i>Psychiatry Research</i> , 2017, 256, 359-364.	3.3	49
44	Modified nutritional counselling to increase motivation to treatment in anorexia nervosa. <i>European Psychiatry</i> , 2005, 20, 186-187.	0.2	48
45	Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 305-315.	3.2	47
46	Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia. <i>Clinical Neurophysiology</i> , 2016, 127, 2149-2160.	1.5	45
47	Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 253-266.	4.5	44
48	EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 653642.	2.6	44
49	COMT Val158Met and BDNF C270T polymorphisms in schizophrenia: a case-control study. <i>Schizophrenia Research</i> , 2005, 73, 27-30.	2.0	42
50	Levosulpiride: a review of its clinical use in psychiatry. <i>Pharmacological Research</i> , 1995, 31, 95-101.	7.1	40
51	Neurophysiological correlates of Avolition-apathy in schizophrenia: A resting-EEG microstates study. <i>NeuroImage: Clinical</i> , 2018, 20, 627-636.	2.7	39
52	Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. <i>International Journal of Psychophysiology</i> , 1999, 34, 293-301.	1.0	38
53	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. <i>Psychological Medicine</i> , 2018, 48, 1359-1366.	4.5	37
54	Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment. <i>International Journal of Psychophysiology</i> , 1992, 13, 283-290.	1.0	35

#	ARTICLE	IF	CITATIONS
55	Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 789179.	2.6	35
56	Neurocognitive indices of executive hypercontrol in obsessive-compulsive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 380-387.	4.5	34
57	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 285-294.	3.2	33
58	Electrophysiological Aberrations Associated with Negative Symptoms in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 21, 129-156.	1.7	32
59	Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. <i>European Neuropsychopharmacology</i> , 2018, 28, 589-602.	0.7	32
60	Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 55-65.	1.7	31
61	Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 264-269.	4.8	30
62	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. <i>European Neuropsychopharmacology</i> , 2020, 34, 76-86.	0.7	30
63	Conditional Associative Learning in Drug-Free Schizophrenic Patients. <i>Neuropsychobiology</i> , 1987, 17, 30-34.	1.9	27
64	Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. <i>Psychological Medicine</i> , 2011, 41, 839-848.	4.5	26
65	Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. <i>Schizophrenia Research</i> , 2016, 174, 172-176.	2.0	25
66	Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. <i>Psychiatry Research - Neuroimaging</i> , 1996, 67, 113-122.	1.8	24
67	NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. <i>Psychiatry Research</i> , 2010, 176, 82-84.	3.3	24
68	Neurocognitive individualized training versus social skills individualized training: A randomized trial in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 69-75.	2.0	24
69	Cerebral connectivity and psychotic personality traits. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 292-299.	3.2	23
70	Disorganization and cognitive impairment in schizophrenia: New insights from electrophysiological findings. <i>International Journal of Psychophysiology</i> , 2019, 145, 99-108.	1.0	23
71	Dynamic brain mapping methodology and application. <i>International Journal of Psychophysiology</i> , 1991, 10, 281-291.	1.0	21
72	Decrease of functional coupling between left and right auditory cortices during dichotic listening: An electroencephalography study. <i>Neuroscience</i> , 2005, 136, 323-332.	2.3	21

#	ARTICLE	IF	CITATIONS
73	Mutation analysis of oxytocin gene in individuals with adult separation anxiety. <i>Psychiatry Research</i> , 2009, 168, 87-93.	3.3	21
74	Lateralization patterns of verbal stimuli processing assessed by reaction time and event-related potentials in schizophrenic patients. <i>International Journal of Psychophysiology</i> , 1988, 6, 167-176.	1.0	19
75	Negative Symptoms in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 8, 28-35B.	1.4	19
76	Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques. <i>Frontiers in Neuroscience</i> , 2020, 14, 632.	2.8	17
77	“Simple schizophrenia”: a controlled MRI and clinical/neuropsychological study. <i>Psychiatry Research - Neuroimaging</i> , 1999, 91, 175-184.	1.8	16
78	Hemispheric lateralization patterns and psychotic experiences in healthy subjects. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 141-154.	1.8	16
79	Acute Effects of Music Therapy in Subjects With Psychosis During Inpatient Treatment. <i>Psychiatry (New York)</i> , 2018, 81, 218-227.	0.7	16
80	C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment. <i>European Neuropsychopharmacology</i> , 1990, 1, 51-54.	0.7	15
81	Brain electrical microstates in subjects with panic disorder. <i>Brain Research Bulletin</i> , 2001, 54, 427-435.	3.0	15
82	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.2	15
83	Lateralization patterns of event-related potential and performance indices in schizophrenia: relationship to clinical state and neuroleptic treatment. <i>International Journal of Psychophysiology</i> , 1991, 10, 225-230.	1.0	13
84	Emotions, Brain Development, and Psychopathologic Vulnerability. <i>CNS Spectrums</i> , 2000, 5, 44-48.	1.2	13
85	Physiological Correlates of Positive Symptoms in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 21, 103-128.	1.7	13
86	Special Report on the Impact of the COVID-19 Pandemic on Clinical EEG and Research and Consensus Recommendations for the Safe Use of EEG. <i>Clinical EEG and Neuroscience</i> , 2021, 52, 3-28.	1.7	13
87	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	2.6	13
88	Cognitive-enhancing effects of aripiprazole: a case report. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2008, 4, 24.	1.2	12
89	SoCIAL &ndash; training cognition in schizophrenia: a pilot study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1947-1956.	2.2	12
90	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 126-136.	2.6	12

#	ARTICLE	IF	CITATIONS
91	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. Journal of Psychiatric Research, 2021, 133, 38-45.	3.1	12
92	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. Brain Sciences, 2021, 11, 1632.	2.3	12
93	Experimental and Theoretical Investigation of Intercalation and Molecular Structure of Organo-Iron Complexes in Montmorillonite. Journal of Physical Chemistry C, 2018, 122, 25422-25432.	3.1	11
94	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia " data from the OPTiMiSE trial. Psychiatry Research, 2020, 289, 112970.	3.3	11
95	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophrenia Research, 2021, 228, 29-35.	2.0	11
96	Influence of Moclobemide on Cognitive Functions of Nine Depressed Patients: Pilot Trial with Neurophysiological and Neuropsychological Indices. Neuropsychobiology, 1996, 33, 48-54.	1.9	10
97	Discrimination of Mode of Action of Anxiolytics using an Integrated Computer Data Bank and Dynamic Brain Mapping (CNS Effects of Diazepam and Lorazepam). International Clinical Psychopharmacology, 1989, 4, 273-284.	1.7	9
98	Treating Schizophrenia: Open Conversations and Stronger Relationships Through Psychoeducation and Shared Decision-Making. Frontiers in Psychiatry, 2020, 11, 761.	2.6	9
99	Schizophrenia and "unmet needs" From diagnosis to care in Italy. European Psychiatry, 2020, 63, e26.	0.2	9
100	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. Schizophrenia Bulletin, 2021, 47, 444-455.	4.3	9
101	Impulsiveness in Patients with Bulimia Nervosa: Electrophysiological Evidence of Reduced Inhibitory Control. Neuropsychobiology, 2013, 68, 116-123.	1.9	8
102	Impact of Reward and Loss Anticipation on Cognitive Control: An Event-Related Potential Study in Subjects With Schizophrenia and Healthy Controls. Clinical EEG and Neuroscience, 2018, 49, 46-54.	1.7	8
103	Nramp1 gene affects selective early steps in macrophage-mediated anti-cryptococcal defense. Medical Microbiology and Immunology, 2001, 189, 209-216.	4.8	7
104	Autism Rating Scale: A New Tool for Characterizing the Schizophrenia Phenotype. Frontiers in Psychiatry, 2021, 12, 622359.	2.6	7
105	&lt;p&gt;The Efficacy, Feasibility And Acceptability Of A Remotely Accessible Use Of CIRCuiTS, A Computerized Cognitive Remediation Therapy Program For Schizophrenia: A Pilot Study&lt;p&gt;. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3103-3113.	2.2	6
106	Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study. Psychological Medicine, 2023, 53, 3471-3479.	4.5	6
107	Survival from coma induced by an intentional 36-g overdose of extended-release quetiapine. Drug and Chemical Toxicology, 2011, 34, 475-477.	2.3	5
108	Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic features. European Psychiatry, 2020, 63, e49.	0.2	5

#	ARTICLE	IF	CITATIONS
109	The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 161-170.	2.0	5
110	Untangling the Factors Contributing to Functional Outcome in Schizophrenia—Reply. <i>JAMA Psychiatry</i> , 2018, 75, 754.	11.0	4
111	Psychophysiology in psychiatry: new perspectives in the study of mental disorders. <i>World Psychiatry</i> , 2002, 1, 166-8.	10.4	4
112	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. <i>Schizophrenia Research</i> , 2022, 240, 193-203.	2.0	4
113	Negative Symptom Domains in Children and Adolescents at Ultra-High Risk for Psychosis: Association With Real-Life Functioning. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	4
114	Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 21-35.	4.5	4
115	Neuroimaging and Psychopathological Domains. , 2019, , 57-155.		3
116	The second-generation assessment scales: Brief negative symptom scale and clinical assessment interview for negative symptoms. <i>European Psychiatry</i> , 2016, 33, S70-S70.	0.2	2
117	The Evolution of Negative Symptom Constructs. <i>European Psychiatry</i> , 2017, 41, S14-S15.	0.2	2
118	31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S50-S51.	4.3	2
119	Neurobiology of Schizophrenia: Electrophysiological Indices. , 2019, , 433-459.		2
120	Quantitative EEG reactivity to neuroleptic challenge in first-episode and chronic schizophrenics. <i>Biological Psychiatry</i> , 1997, 42, 64S.	1.3	1
121	Effects of antipsychotics on cognitive functions: an ERP study in healthy controls. <i>European Psychiatry</i> , 2011, 26, 1267-1267.	0.2	1
122	Social skills vs. Neurocognitive training in psychotic patients. <i>European Psychiatry</i> , 2011, 26, 1475-1475.	0.2	1
123	Neurophysiological correlates of negative symptom domains: an auditory oddball study in schizophrenia. <i>European Neuropsychopharmacology</i> , 2016, 26, S506-S507.	0.7	1
124	Relationships between neurocognition, social cognition and functional outcome in schizophrenia. <i>European Psychiatry</i> , 2016, 33, S67-S67.	0.2	1
125	Neurocognitive Predictors of Social Cognition in Subjects with Schizophrenia and their First-degree Relatives. <i>European Psychiatry</i> , 2017, 41, S40-S40.	0.2	1
126	Resilience in people with schizophrenia. Results from the Italian Network for Research on Psychoses. <i>European Journal of Public Health</i> , 2017, 27, .	0.3	1



#	ARTICLE	IF	CITATIONS
127	Electrophysiological and Neuroimaging Research on Negative Symptoms: Future Challenges. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 3-5.	1.7	1
128	Quantitative EEG in Psychiatry: From Research to Clinical Applications. <i>European Psychiatry</i> , 1997, 12, 105s-105s.	0.2	0
129	EEG mapping before and after antipsychotic treatment in chronic and first-episode schizophrenics. <i>European Psychiatry</i> , 1998, 13, 197S-197S.	0.2	0
130	S21.02 Cognitive dysfunctions in psychotic patients: Relationship with symptoms and antipsychotic treatment. <i>European Psychiatry</i> , 2000, 15, 252s-252s.	0.2	0
131	Topographic and tomographic EEG changes after a single oral dose of antipsychotic drugs in healthy young subjects. <i>European Psychiatry</i> , 2007, 22, S160-S161.	0.2	0
132	A psychophysiological investigation of emotional processing in subjects with panic disorder. <i>European Psychiatry</i> , 2007, 22, S289.	0.2	0
133	ERP changes induced by antipsychotic drugs. <i>European Psychiatry</i> , 2008, 23, S78.	0.2	0
134	Social skills and neurocognitive individualized training in patients with schizophrenia. <i>European Psychiatry</i> , 2008, 23, S137-S138.	0.2	0
135	Perception of body shape in bulimia nervosa: An ERP study. <i>European Psychiatry</i> , 2011, 26, 741-741.	0.2	0
136	EPA-1469 "Neurocognitive training and functional outcome: is there any evidence of a direct relationship. <i>European Psychiatry</i> , 2014, 29, 1.	0.2	0
137	Reward Anticipation and Negative Symptoms in Schizophrenia: an Electrophysiological Investigation. <i>European Psychiatry</i> , 2015, 30, 280.	0.2	0
138	Negative symptoms domains: pathways to functional outcome in schizophrenia. <i>European Neuropsychopharmacology</i> , 2016, 26, S123.	0.7	0
139	Electrophysiological mechanisms underlying ERP amplitude reduction in patients with schizophrenia: A time-frequency analysis. <i>European Psychiatry</i> , 2016, 33, S104-S104.	0.2	0
140	The social cognition individualized activities lab: Implementation of a new remediation intervention for social cognition. <i>European Psychiatry</i> , 2016, 33, S567-S567.	0.2	0
141	Neurophysiological correlates of negative symptom domains in patients with schizophrenia. <i>European Psychiatry</i> , 2016, 33, s265-s265.	0.2	0
142	A multicentric study on cognitive functions in a large sample of patients with schizophrenia and their unaffected first-degree relatives. <i>European Psychiatry</i> , 2016, 33, s244-s244.	0.2	0
143	A comprehensive systematic screening protocol for assessment of medical comorbidities in schizophrenia. <i>European Psychiatry</i> , 2016, 33, S574-S574.	0.2	0
144	Relation between EEG source functional connectivity and the negative symptom severity in schizophrenia: a preliminary report from a multicentre study. <i>European Psychiatry</i> , 2016, 33, s246-s246.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Avolition in schizophrenia: associations with trait and state anhedonia. <i>European Psychiatry</i> , 2016, 33, s246-s246.	0.2	0
146	Resting state functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia. <i>European Neuropsychopharmacology</i> , 2017, 27, S67.	0.7	0
147	Applicability and Feasibility of the Italian Version of the Cognitive Remediation Program Circuits: A Pilot Study. <i>European Psychiatry</i> , 2017, 41, s786-s786.	0.2	0
148	Validation of the Italian Version of the "abnormal Bodily Phenomena Questionnaire" in a Sample of Patients with Schizophrenia: Preliminary Data. <i>European Psychiatry</i> , 2017, 41, S80-S80.	0.2	0
149	The Impact of Premorbid Functioning on Outcome Indices in a Large Sample of Italian Patients with Schizophrenia. <i>European Psychiatry</i> , 2017, 41, S96-S96.	0.2	0
150	Effects of chronic antipsychotic treatment on neurophysiological correlates of the auditory oddball task in schizophrenia: A preliminary report from a multicentre study. <i>European Psychiatry</i> , 2017, 41, S192-S192.	0.2	0
151	VTA-insula Connectivity and Avolition in Subjects with Schizophrenia. <i>European Psychiatry</i> , 2017, 41, S57-S57.	0.2	0
152	Functional connectivity of the ventral tegmental area and avolition in schizophrenia: A resting state functional MRI study. <i>European Psychiatry</i> , 2017, 41, S196-S196.	0.2	0
153	Characterization of different subtypes of schizophrenia: Premorbid functioning, neurophysiological differences, functional outcomes. <i>European Psychiatry</i> , 2017, 41, S52.	0.2	0
154	Electrophysiological Correlates of Negative Symptom Domains in Schizophrenia. <i>European Psychiatry</i> , 2017, 41, S96-S97.	0.2	0
155	Disorganization in Schizophrenia: A Resting EEG Study. <i>European Psychiatry</i> , 2017, 41, S100-S100.	0.2	0
156	Cognitive Dysfunctions in the Psychoses and their Impact on Patients' Social Functioning. <i>European Psychiatry</i> , 2017, 41, S48-S48.	0.2	0
157	A Hybrid Effectiveness-implementation Trial of Wellness Self-management Program for Patients with Severe Mental Illness in an Italian Day Hospital Setting. <i>European Psychiatry</i> , 2017, 41, S96-S96.	0.2	0
158	T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION?. <i>Schizophrenia Bulletin</i> , 2018, 44, S196-S197.	4.3	0
159	F114. DISORGANIZATION AND COGNITIVE DYSFUNCTIONS IN SCHIZOPHRENIA: A STUDY OF RESTING STATE EEG. <i>Schizophrenia Bulletin</i> , 2018, 44, S264-S264.	4.3	0
160	F111. ELECTROPHYSIOLOGICAL CORRELATES OF AVOLITION-APATHY DOMAIN IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S263-S263.	4.3	0
161	White matter structural connectivity abnormalities in subjects with deficit schizophrenia: A diffusion tensor imaging study. <i>European Neuropsychopharmacology</i> , 2019, 29, S110.	0.7	0
162	17.2 NEGATIVE SYMPTOMS IN THE OPTIMISE COHORT: PREDICTION OF SHORT-TERM REMISSION STATE AND ASSOCIATION WITH PSYCHOSOCIAL FUNCTIONING. <i>Schizophrenia Bulletin</i> , 2019, 45, S116-S116.	4.3	0

#	ARTICLE	IF	CITATIONS
163	Academic and social functioning in early life epochs in schizophrenia patients and first-degree unaffected relatives. <i>European Neuropsychopharmacology</i> , 2019, 29, S336.	0.7	0
164	A feasibility, acceptability and validation study of the Italian Version of a new cognitive remediation program for psychotic patients " CIRCuiTS. <i>European Neuropsychopharmacology</i> , 2019, 29, S318-S319.	0.7	0
165	P.778 Electrophysiological indices and expressive deficit domain of negative symptoms in subjects with schizophrenia. <i>European Neuropsychopharmacology</i> , 2020, 40, S442.	0.7	0
166	P.779 Multivariate investigations of electrophysiological indices for the diagnosis and prognosis of schizophrenia. <i>European Neuropsychopharmacology</i> , 2020, 40, S442-S443.	0.7	0
167	P.307 Resting state MRI functional connectivity and negative symptoms in subjects with schizophrenia. <i>European Neuropsychopharmacology</i> , 2021, 44, S44-S45.	0.7	0
168	Selected E-INSR 2004 Conference Presentation Abstracts. <i>Journal of Neurotherapy</i> , 2005, 9, 103-108.	0.9	0
169	Haloperidol-Induced Changes of Computerized Electroencephalogram Topography in Drug-Free Schizophrenic Patients. , 1993, , 245-250.		0
170	P.0589 Resting-state functional connectivity of the ventral tegmental area and negative symptoms in subjects with schizophrenia: a resting-state functional MRI study. <i>European Neuropsychopharmacology</i> , 2021, 53, S431-S432.	0.7	0
171	P.0592 Investigating the relationships of N100-P3b with symptom dimensions and cognitive impairments in subjects with chronic schizophrenia. <i>European Neuropsychopharmacology</i> , 2021, 53, S432-S433.	0.7	0